CFTR Biomarkers, Canada

Registration Status: Completed

Objective: The purpose is to identify promising novel candidate plasma and nasal cell biomarkers that indicate responsiveness to CF Modulator therapy in cystic fibrosis adult patients. Using a non-targeted approach, we will identify proteins to discover novel candidate plasma biomarkers that change in levels of expression from untreated to treated state, as well as comparing to healthy controls. The purpose of the optional genetics study is to discover new information from RNA in the blood that indicate CF modulator therapy response in CF patients. We will focus on the RNA molecules that change in levels between treated and untreated states.

Registered Biobank Name	CFTR Biomarkers
Biobank Leader	Bradley Quon
Country	Canada
Email for biobank inquiries	Bradley.quon@hli.ubc.ca
Principal Investigator	Bradley Quon
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).